CanaryBio Surpasses 70% Patient Enrollment in Global Phase 3 Clinical Trial

[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 4th that the global Phase 3 clinical trial recruitment for Oregovomab, conducted on ovarian cancer patients, has surpassed 70%. Out of the total target of 602 patients, 423 have been recruited, exceeding 70%.

This global Phase 3 clinical trial is divided into two cohorts: adjuvant chemotherapy and neoadjuvant chemotherapy. The US FDA has indicated that approval of the new drug is possible if even one of the cohorts is successful. The recruitment speed for the neoadjuvant chemotherapy cohort is relatively faster, and interim results are expected to be available in the second quarter of next year.

Oregovomab showed encouraging results in the global Phase 2 clinical trial, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months. The global Phase 3 clinical trial of Oregovomab is being conducted under the clinical leadership of Dr. Angeles Secord (Duke University Cancer Institute, USA) at 152 sites across 16 countries, targeting newly diagnosed ovarian cancer patients.

This content was produced with the assistance of AI translation services.